<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794312</url>
  </required_header>
  <id_info>
    <org_study_id>LT4020-PIII-12/11</org_study_id>
    <nct_id>NCT01794312</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer</brief_title>
  <official_title>Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of T4020 versus vehicle.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">December 19, 2017</completion_date>
  <primary_completion_date type="Actual">December 19, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Reduction in Neurotrophic the Keratitis/Ulcer Area on Day28</measure>
    <time_frame>Day 28</time_frame>
    <description>Reduction in neurotrophic ulcer/keratitis area of 50% or more</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Treatment-emergent Adverse Event</measure>
    <time_frame>From the first visit to the final visit performed by the patient + 1 month later, assessed up to 71 days</time_frame>
    <description>With at least one TEAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change from baseline in far best-corrected visual acuity (LogMAR) in the pathologic eye</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Keratitis</condition>
  <condition>Corneal Ulcer</condition>
  <arm_group>
    <arm_group_label>T4020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop every 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop every 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>T4020</intervention_name>
    <arm_group_label>T4020</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients diagnosed with one chronic keratitis/corneal ulcer

          -  Patients who signed and dated informed consent

        Exclusion Criteria:

          -  Patient under 18 years

          -  Patient with a perforated corneal ulcer OR any risk of immediate perforation of
             corneal ulcer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Development Director</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 25, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <results_first_submitted>July 16, 2019</results_first_submitted>
  <results_first_submitted_qc>September 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 7, 2019</results_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Ulcer</mesh_term>
    <mesh_term>Keratitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 17, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT01794312/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T4020</title>
          <description>One drop every 2 days</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>One drop every 2 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T4020</title>
          <description>One drop every 2 days</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>One drop every 2 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="17"/>
                    <measurement group_id="B2" value="65.2" spread="17.8"/>
                    <measurement group_id="B3" value="63.8" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Reduction in Neurotrophic the Keratitis/Ulcer Area on Day28</title>
        <description>Reduction in neurotrophic ulcer/keratitis area of 50% or more</description>
        <time_frame>Day 28</time_frame>
        <population>Modified Intent to treat (m-ITT): All randomised patients received at least 1 IMP dose, with at least 1 baseline and 1 post-baseline efficacy assessment.
For the primary outcome measure, 4 patients (2 in the T4020 and Vehicle groups) had no data for the reduction from baseline of corneal ulcer/keratitis area and were not included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>T4020</title>
            <description>One drop every 2 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>One drop every 2 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Reduction in Neurotrophic the Keratitis/Ulcer Area on Day28</title>
          <description>Reduction in neurotrophic ulcer/keratitis area of 50% or more</description>
          <population>Modified Intent to treat (m-ITT): All randomised patients received at least 1 IMP dose, with at least 1 baseline and 1 post-baseline efficacy assessment.
For the primary outcome measure, 4 patients (2 in the T4020 and Vehicle groups) had no data for the reduction from baseline of corneal ulcer/keratitis area and were not included in this analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Treatment-emergent Adverse Event</title>
        <description>With at least one TEAE</description>
        <time_frame>From the first visit to the final visit performed by the patient + 1 month later, assessed up to 71 days</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>T4020</title>
            <description>One drop every 2 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>One drop every 2 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Treatment-emergent Adverse Event</title>
          <description>With at least one TEAE</description>
          <population>Safety Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity</title>
        <description>Change from baseline in far best-corrected visual acuity (LogMAR) in the pathologic eye</description>
        <time_frame>Baseline and Day 28</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>T4020</title>
            <description>One drop every 2 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>One drop every 2 days</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity</title>
          <description>Change from baseline in far best-corrected visual acuity (LogMAR) in the pathologic eye</description>
          <population>Safety set</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.055" spread="0.362"/>
                    <measurement group_id="O2" value="-0.035" spread="0.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first visit to the final visit performed by the patient + 1 month later, assessed up to 71 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T4020</title>
          <description>One drop 4 times per week</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>One drop 4 times per week</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Corneal neovascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Corneal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes Simplex ophthalmic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Corneal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Keratitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Conjuncticitis allergic, diplopia</sub_title>
                <description>Ocular adverse event in the other eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Acanthamoeba keratitis</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Conjunctival hemorrhage</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Corneal epithelium defect</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Corneal erosion</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Corneal neovascularisation</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Corneal perforation</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Neurotrophic keratopathy</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site reaction</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <description>Non ocular adverse event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <description>Non ocular adverse event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hypopyon, Keratitis bacterial, Keratitis herpetic, Corneal infection, Dacryocanaliculitis, Dacryocys</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Device related infection, Gastroenteritis, Oral herpes, Urinary tract infection</sub_title>
                <description>Non ocular adverse event</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture, Road traffic accident</sub_title>
                <description>Non ocular adverse event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Vital dye staining cornea present</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Non ocular adverse event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Non ocular adverse event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Begnin prostatic hyperplasia</sub_title>
                <description>Non ocular adverse event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail bed bleeding</sub_title>
                <description>Non ocular adverse event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <description>Non ocular adverse event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <description>Ocular adverse event in pathologic eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Director</name_or_title>
      <organization>Laboratoires Tha</organization>
      <phone>+33(0)473981414</phone>
      <email>Corentin.LECAMUS@theapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

